Biotechnology

CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041

SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Company has received a No Objection Letter from...

2021-11-22 20:00 3214

Breakthrough Chemotherapy Heart Protection Discovery for Australian Biotech

* Race Oncology's drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline's are the most used and effective anti-cancer drugs, yet they can cause serious heart damage. * The preclinical research also demonstrated Zantrene's ability t...

2021-11-22 09:24 3354

DSM recognized for advancing sustainable food commitments and novel science-based solutions across Asia Pacific

SINGAPORE, Nov. 22, 2021 /PRNewswire/ -- Royal DSM, a global purpose-led science-based company active in Health, Nutrition and Bioscience has been awarded 'Asia's Most Sustainable Company of the Year' by Asia Corporate Excellence & Sustainability (ACES) Awards.

2021-11-22 09:00 3175

Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-22 08:00 4499

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...

2021-11-21 17:09 4154

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...

2021-11-21 17:02 3966

US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics

LONDON, Nov. 20, 2021 /PRNewswire/ -- Datar Cancer Genetics, a leading cancer research company focussed on early detection of cancers today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage Breast Cancer...

2021-11-20 08:00 6256

Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time

SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ -- At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co., Ltd. will depart from Shenzhen Bao'an International Airport and will arrive in Jakarta...

2021-11-19 18:52 2433

Vazyme Attends Medica 2021 in Germany to Accelerate Its Global Market Expansion

DUSSELDORF, Germany, Nov. 19, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme (688105.SH) recently attended Medica 2021 in Germany—one of the world's largest events for the medical sector—to accelerate the expansion of its international business. At the event, Vazyme introduced its newe...

2021-11-19 15:18 4297

ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine

SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...

2021-11-19 13:14 1698

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

-  Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights -  ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China -  Exciting ATG-008 (mTORC1/2 inhibitor) Signal, ATG-017 (ER...

2021-11-19 13:00 4799

Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

SHANGHAI and Hong Kong, Nov. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-11-19 08:30 3956

Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

LOWER GWYNEDD, Penn., Nov. 18, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing wi...

2021-11-19 08:00 1984

JBS is entering the cultivated protein market with the acquisition of BioTech Foods and the construction of a plant in Europe

The new production plant in Spain will scale up production. The Company is also going to build a research & development center in biotechnology and cultivated protein inBrazil.  The investments total US$100 million  SÃO PAULO, Nov. 18, 2021 /PRNewswire/ -- JBS, the largest global protein compa...

2021-11-18 22:00 3524

Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the closing of an oversubscribed Series B financing, which raised more than$91...

2021-11-18 20:00 3280

Prenetics Circle HealthPod joins forces with Ian Chan, member of popular boy group "Mirror" to achieve zero distancing

* Circle HealthPod is one of the world's most advanced home detection systems * Technology developed by the University of Oxford, with PCR-quality results in around 20 minutes * Ian sings the song "It's a Brand New Day" to empower individuals to resume normal life and drive healthier communi...

2021-11-18 09:08 3368

Silk Medical Aesthetics Announces Feasibility Clinical Trial Results for its All-Natural Dermal Filler

BOSTON, Nov. 18, 2021 /PRNewswire/ -- Silk Medical Aesthetics, alongside sister companyEvolved by Nature, the developer of Activated Silk™ biotechnology, announced today the results of a 44-patient feasibility study under an FDA-approved IDE clinical trial for its all-natural dermal filler for N...

2021-11-18 08:20 2791

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine m...

2021-11-17 23:23 4264

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

NANJING, China, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today an...

2021-11-17 22:00 1905

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2022 Financial Results

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2021-11-17 20:00 2640
1 ... 312313314315316317318 ... 349